Showing 209–224 of 271 results
-
TAVALISSE (fostamatinib disodium hexahydrate) tablets, for oral use Initial U.S. Approval: 2018
Read more -
TECENTRIQ (atezolizumab) injection, for intravenous use.
Read more -
TECVAYLI (teclistamab-cqyv) injection
Read more -
TEGSEDI (inotersen) injection, for subcutaneous use.
Read more -
TEPEZZA (teprotumumab-trbw) for injection, for intravenous use Initial U.S. Approval: 2020
Read more -
TERLIVAZ (terlipressin) for injection
Read more -
TEVIMBRA (tislelizumab-jsgr) injection
Read more -
TEZSPIRE (tezepelumab-ekko) injection
Read more -
TIBSOVO (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018
Read more -
TIVDAK (tisotumab vedotin-tftv) for injection
Read more -
TIVICAY (dolutegravir) Tablets for Oral Use. Initial U.S. Approval: 2013
Read more -
TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. Initial U.S. Approval: 2019
Read more -
TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral use Initial U.S. Approval: 2014
Read more -
TRODELVY (sacituzumab govitecan-hziy) for injection, for intravenous use
Read more -
TRUQAP (capivasertib) tablets
Read more -
TRUVADA (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2004
Read more
